Evidence map›Paper›PMID 19847160›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2010

Serotonergic and noradrenergic modulation of emotion processing by single dose antidepressants.

Annette Beatrix Brühl, Tina Kaffenberger, Uwe Herwig

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 63 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Effects of Escitalopram Administration on Face Processing in Intermittent Explosive Disorder: An fMRI Study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Selective serotonin reuptake inhibitor treatment retunes emotional valence in primate ventral striatum.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Article
  12. Impact of FAAH genetic variation on fronto-amygdala function during emotional processing.European archives of psychiatry and clinical neuroscience · 2019
    Article
  13. Review
  14. Article
  15. Article
  16. Altered Functional Magnetic Resonance Imaging Markers of Affective Processing During Treatment of Late-Life Depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2016
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 3 countries.

Annette Beatrix BrühlPsychiatric University Hospital Zürich, Clinic for Social and General Psychiatry, Zürich, Switzerland. annette.bruehl@puk.zh.ch
Tina Kaffenberger
Uwe Herwig
University of Zurich · CHUniversity Psychiatric Hospital · SI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serotonergic and noradrenergic pathways are the main targets of antidepressants. Their differential effects on emotion processing-related brain activation are, however, to be further characterized. We aimed at elucidating the neural sites of action of an acute differential serotonergic and noradrenergic influence on an emotion-processing task, which was earlier shown to be associated with depressiveness. In a single-blind pseudo-randomized crossover study, 21 healthy subjects (16 subjects finally included in the analysis) participated to ingest a single dose at three time points of either 40 mg citalopram, a selective serotonin-reuptake inhibitor, 8 mg reboxetine, a selective noradrenaline-reuptake inhibitor, or placebo 2-3 h before functional magnetic resonance imaging (fMRI). During fMRI, subjects performed a task comprising the anticipation and perception of pictures of either 'known' (positive, negative, neutral) or 'unknown' valence (randomly 50% positive or negative). In direct comparison with citalopram and with placebo, reboxetine increased brain activity in the medial thalamus. Citalopram modulated certain prefrontal and insular areas more prominently. Other frontal and parieto-occipital areas were modulated by both drugs. In conclusion, the functional network involved in emotional information processing could be modulated by the acute application of selective noradrenergic and serotonergic drugs revealing a noradrenergic effect in thalamic and frontal areas, and a prefrontal and insular focus of serotonergic modulation. These findings could have implications for future selection criteria concerning personalized antidepressant medication in depression.

Indexed as

AdultAnalysis of VarianceAntidepressive AgentsBrainBrain MappingCitalopramExpressed EmotionFemaleHumansImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleMorpholinesNeural PathwaysNorepinephrineOxygenAntidepressive AgentsCitalopramMorpholinesNorepinephrineOxygenReboxetineSerotonin

Identifiers

PMID19847160
PMCPMC3055388
OpenAlexW2117459380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.